Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme

Inclusion Criteria: * Age 18 or older * Diagnosis of histologically confirmed glioblastoma (WHO grade IV). Subjects with an original histologic diagnosis of low grade glioma or anaplastic glioma (WHO grade II or III) are eligible if a subsequent histological diagnosis of glioblastoma is made * Patients whose tumor is determined to be unmethylated * Patients with incomplete resection as determined by residual, measurable gadolinium or contrast-enhancing lesion or lesions * Recent resection of glioblastoma within 4 weeks of study entry. Patients who have only had a tumor biopsy and who are considered unresectable are eligible (but based on the study accrual this subset of patients with unresectable tumor may be considered for separate analysis) * Eastern Cooperative Oncology Group Performance Status (ECOG PS) of ≤ 2 (see appendix A) * Willing to remain abstinent from consuming alcohol while on DSF * No prior radiation or chemotherapy * Meets the following laboratory criteria: * Absolute neutrophil count ≥ 1,500/mcL (microliter) * Platelets ≥ 100,000/mcL * Hemoglobin \> 10.0 g/dL (grams/deciliter) (transfusion and/or ESA (erythropoiesis-stimulating agent) allowed) * Total bilirubin and alkaline phosphatase ≤ 2x institutional upper limit of normal (ULN) * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 3 x ULN * Blood urea nitrogen (BUN) and creatinine \< 1.5 x ULN * Able to take oral medication * Able to understand and willing to sign an institutional review board (IRB)-approved written informed consent document (legally authorized representative permitted) Exclusion Criteria: * Radiographic evidence of leptomeningeal dissemination, extensive intraparenchymal dissemination, infratentorial tumor, or metastatic disease to sites remote from the supratentorial brain * Enrolled in another clinical trial testing a novel therapy or drug * Received prior radiation therapy or chemotherapy for glioblastoma * History of allergic reaction/hypersensitivity to DSF (without alcohol) or copper. * Treatment with the following medications that may interfere with metabolism of DSF: warfarin (unless otherwise chosen by the study PI who will actively adjust Coumadin dose to consistently maintain a safe, therapeutic international normalized ratio (INR) \< 3, theophylline, amitriptyline, isoniazid, metronidazole, phenytoin, phenobarbital, chlorzoxazone, halothane, imipramine, chlordiazepoxide, diazepam. (Note: lorazepam and oxazepam are not affected by the P450 system and are not contraindicated with DSF). * Active severe hepatic or renal disease * Grade 2 or higher peripheral neuropathy or ataxia per NCI CTCAE version 4.0 (2009) * History of idiopathic seizure disorder schizophrenia, or psychosis unrelated to glioblastoma, corticosteroid, or anti-epileptic medications * History of Wilson's or Gilbert's disease * Current excessive use of alcohol